MALARIA FALCIPARUM

This study tested a new malaria vaccine made from genetically weakened parasites that stop growing in the liver and cannot cause blood-stage infection. The goal was to see if it is safe and triggers a strong immune response. The trial involved 75 healthy adults and children in Bu…

This early-stage trial tested a new malaria vaccine called AMA1-DiCo in 66 healthy adults—some in Europe never exposed to malaria, and some in Africa who were. The vaccine was given with one of two adjuvants (GLA-SE or Alhydrogel) to boost immune response. The main goal was to ch…

This study looked at whether finding and treating low-density malaria infections (infections with very few parasites) in children can improve their health and well-being over time. 600 children in Tanzania, aged 6 months to 10 years, took part. The goal was to see if this approac…

This study tested a monoclonal antibody called TB31F in 167 adults and children in Mali who are regularly exposed to malaria. The goal was to see if the antibody is safe and can reduce the spread of the malaria parasite from humans to mosquitoes. Participants received either the …

This study tests a single injection of a new long-acting malaria drug called MMV371 in 32 healthy adults. The main goal is to check if it is safe and how the body processes it. Participants receive either the drug or a placebo and are monitored for about 12 weeks for side effects…

This completed study in western Kenya looked at how well different malaria drugs work and whether the parasites are becoming resistant. Researchers tested four artemisinin-based combination therapies across 28 health facilities over 28 months, involving 316 people with uncomplica…

This study tested a new experimental drug called MMV367 in 12 healthy adults. Participants were intentionally infected with a controlled, low-level malaria infection to see how well the drug works and how safe it is. The goal was to measure how the body processes the drug and how…